Biotechnology - Amgen

Filter

Current filters:

Amgen

Popular Filters

1 to 25 of 135 results

Anthera Pharma licenses Japan rights for blisibimod to Zenyaku Kogyo

Anthera Pharma licenses Japan rights for blisibimod to Zenyaku Kogyo

16-12-2014

US development-stage biophama company Anthera Pharmaceuticals has entered into an exclusive licensing…

AmgenAnthera PharmaceuticalsBiotechnologyblisibimodJapanLicensingOncologyZenyaku Kogyo

Plans unveiled for Singapore’s biologics manufacturing industry

Plans unveiled for Singapore’s biologics manufacturing industry

13-12-2014

The Singapore Workforce Development Agency (WDA), Singapore Economic Development Board (EDB) and Biopharmaceutical…

AbbVieAmgenBaxterBiotechnologyGlaxoSmithKlineLonzaNovartisProductionRocheSingapore

FDA approves new indication for Amgen's Xgeva

FDA approves new indication for Amgen's Xgeva

08-12-2014

USA-based Amgen says the US Food and Drug Administration has approved a new indication for Xgeva (denosumab),…

AmgenBiotechnologyOncologyRare diseasesRegulationUSAXgeva

Sandoz demonstrates safety and efficacy of Neupogen biosimilar

Sandoz demonstrates safety and efficacy of Neupogen biosimilar

08-12-2014

Sandoz, the generics subsidiary of Swiss pharma major Novartis, has today released Phase III data that…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyResearchSandoz

ASH 2014: Amgen and Onyx report primary endpoint met in Kyprolis combination trial

ASH 2014: Amgen and Onyx report primary endpoint met in Kyprolis combination trial

08-12-2014

USA-based Amgen and its subsidiary Onyx Pharmaceuticals announced the results of the Phase III ASPIRE…

AmgenBiotechnologyDexamethasoneKyprolisOncologyOnyx PharmaceuticalsResearchRevlimid

US FDA grants earlier approval for Amgen’s Blincyto for rare form of lymphoblastic leukemia

US FDA grants earlier approval for Amgen’s Blincyto for rare form of lymphoblastic leukemia

04-12-2014

Ahead of the anticipated decision date, the US Food and Drug Administration yesterday approved Blincyto…

AmgenBiotechnologyblinatumomabBlincytoOncologyRegulationUSA

AbbVie acquires API facility in Singapore; Amgen completes new unit

AbbVie acquires API facility in Singapore; Amgen completes new unit

26-11-2014

US pharma major AbbVie has acquired a small-molecule active pharmaceutical ingredient (API) manufacturing…

AbbVieAmgenBiotechnologyGenericsProductionSingapore

Amgen halts all its trials of rilotumumab in advanced gastric cancer

24-11-2014

USA-based Amgen has terminated all company-sponsored clinical studies of rilotumumab in advanced gastric…

AmgenBiotechnologyOncologyResearchrilotumumab

AstraZeneca and Amgen's  brodalumab achieves primary endpoint in Phase III trial for plaque psoriasis

AstraZeneca and Amgen's brodalumab achieves primary endpoint in Phase III trial for plaque psoriasis

12-11-2014

Anglo-Swedish drug major AstraZeneca and USA-based Amgen, the world’s largest independent biotech firm,…

AmgenAstraZenecaBiotechnologybrodalumabDermatologicalsResearchStelara

Amgen’s trebananib disappoints in ovarian cancer trial

Amgen’s trebananib disappoints in ovarian cancer trial

04-11-2014

USA-based Amgen, the world’s largest independent biotech firm, revealed that a late-stage trial of…

AmgenBiotechnologyOncologyResearchtrebananib

Xencor regains rights to XmAb5871 from Amgen

29-10-2014

US drug developer Xencor revealed yesterday that it has regained all development and commercial rights…

AmgenAnti-Arthritics/RheumaticsBiotechnologyImmunologicalsLicensingResearchXencorXmAb5871

Despite restructuring costs, Amgen’s third-qtr beats expectations

Despite restructuring costs, Amgen’s third-qtr beats expectations

28-10-2014

US biotech major Amgen posted a fall in earnings for the third-quarter of 2014, due to restructuring,…

AmgenBiotechnologyFinancialThousand Oaks, CaliforniaUSA

Amgen advised to consider ‘radical’ split by lead investor

Amgen advised to consider ‘radical’ split by lead investor

22-10-2014

One of Amgen’s largest shareholders has said the USA-based biotechnolgy comapny would be better off…

AmgenBiotechnologyFinancialThousand Oaks, CaliforniaUK

Amgen sues Sanofi and Regeneron over alleged patent infringement

19-10-2014

USA-based Amgen has filed a law suit in the US District Court of Delaware against French pharma major…

alirocumabAmgenBiotechnologyCardio-vascularevolocumabLegalPatentsRegeneron PharmaceuticalsSanofiUSA

Ph III study of Amgen’s Humira biosimilar ABP 501 meets endpoint in psoriasis

Ph III study of Amgen’s Humira biosimilar ABP 501 meets endpoint in psoriasis

09-10-2014

US biotech major Amgen says its Phase III study evaluating the efficacy and safety of its biosimilar…

AbbVieABP 501AmgenAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyDermatologicalsHumiraResearchUSA

Amgen files BLA for BiTE immunotherapy blinatumomab

Amgen files BLA for BiTE immunotherapy blinatumomab

22-09-2014

USA-based Amgen has submitted a Biologics License Application (BLA) to the US Food and Drug Administration…

AmgenBiotechnologyblinatumomabOncologyRegulationUSA

Amgen updates on Prolia in postmenopausal osteoporosis

Amgen updates on Prolia in postmenopausal osteoporosis

16-09-2014

USA-based Amgen has released results from a new exploratory analysis of the open-label extension study…

AmgenAnti-Arthritics/RheumaticsBiotechnologyProliaResearchWomen's Health

Green Cross Neulapeg biosimilar approved in South Korea

28-08-2014

South Korea’s Green Cross says that the country’s Ministry of Food and Drug Safety has granted marketing…

AmgenAsia-PacificBiosimilarsBiotechnologyGreen CrossNeulapegNeulastaOncologyRegulation

FDA priority review for Amgen’s ivabradine in CHF

FDA priority review for Amgen’s ivabradine in CHF

27-08-2014

The US Food and Drug Administration has granted priority review designation for US biotech giant Amgen’s…

AmgenBiotechnologyCardio-vascularivabradineRegulationServierUSA

1 to 25 of 135 results

Back to top